ロード中...
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
BACKGROUND: Different bone‐modifying agents like bisphosphonates and receptor activator of nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men with prostate cancer and bone metastases to prevent skeletal‐related events (SREs). SREs such as pathologic fractures, s...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2020
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095056/ https://ncbi.nlm.nih.gov/pubmed/33270906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013020.pub2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|